Role of gyrB mutations in pre-extensively and extensively drug-resistant tuberculosis in Thai clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 9, 2016, Pages 5189-5197

  Disratthakit, Areeya ^a   Prammananan, Therdsak ^b,c   Tribuddharat, Chanwit ^a   Thaipisuttikul, Iyarit ^a   Doi, Norio ^d   Leechawengwongs, Manoon ^c   Chaiprasert, Angkana ^a,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c Siriraj Foundation   (Thailand)

^d RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 (7 AMINO 7 METHYL 5 AZASPIRO[2.4]HEPTAN 5 YL) 6 FLUORO 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) B; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; SPARFLOXACIN; 7-(7-AMINO-7-METHYL-5-AZASPIRO(2.4)HEPTAN-5-YL)-6-FLUORO-1-(2-FLUORO-1-CYCLOPROPYL)-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID; AMINOPYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DNA SUPERCOILING; DRUG RESISTANT TUBERCULOSIS; ENZYME INHIBITION ASSAY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; IC50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; MYCOBACTERIUM TUBERCULOSIS; THAILAND; TUBERCULOSIS, PULMONARY;

AMINOPYRIDINES; ANTITUBERCULAR AGENTS; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; GENE EXPRESSION; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; THAILAND; TUBERCULOSIS, PULMONARY;

EID: 84983479186     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00539-16     Document Type: Article

References (51)

1. WHO. 2015. Global tuberculosis report 2015. World Health Organization, Geneva, Switzerland.
2. WHO. 2009. Treatment of tuberculosis: guidelines, 4th ed. World Health Organization, Geneva, Switzerland.
3. Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. 2013. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 18(40):pii=20601. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleIdo=20601.
4. Andriole VT. 2005. The quinolones: past, present, and future. Clin Infect Dis 41:S113-S119. http://dx.doi.org/10.1086/428051.
5. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684-692. http://dx.doi.org/10.1164/rccm.201001-0077OC.
6. Ahmad Z, Minkowski A, Peloquin CA, Williams KN, Mdluli KE, Grosset JH, Nuermberger EL. 2011. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother 55:1781-1783. http://dx.doi.org/10.1128/AAC.01514-10.
7. Disratthakit A, Doi N. 2010. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Antimicrob Agents Chemother 54:2684-2686. http://dx.doi.org/10.1128/AAC.01545-09.
8. Ahmed I, Jabeen K, Inayat R, Hasan R. 2013. Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate. Antimicrob Agents Chemother 57:2522-2525. http://dx.doi.org/10.1128/AAC.02020-12.
9. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 12:7-11. http://dx.doi.org/10.1089/mdr.2006.12.7.
10. Chaiprasert A, Srimuang S, Tingtoy N, Makhao N, Sirirudeeporn P, Tomnongdee N, Theankeaw O, Charoensook S, Leechawengwongs M, Prammananan T. 2014. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update. Int J Tuberc Lung Dis 18:961-963. http://dx.doi.org/10.5588/ijtld.13.0197.
11. Prammananan T, Arjratanakool W, Chaiprasert A, Tingtoy N, Leechawengwong M, Asawapokee N, Leelarasamee A, Dhiraputra C. 2005. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 9:216-219.
12. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjo M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM. 2015. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol 53:2961-2969. http://dx.doi.org/10.1128/JCM.01257-15.
13. Ambur OH, Davidsen T, Frye SA, Balasingham SV, Lagesen K, Rognes T, Tonjum T. 2009. Genome dynamics in major bacterial pathogens. FEMS Microbiol Rev 33:453-470. http://dx.doi.org/10.1111/j.1574-6976.2009.00173.x.
14. Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, Mayer C, Aubry A. 2012. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 56:1990-1996. http://dx.doi.org/10.1128/AAC.06272-11.
15. Piton J, Petrella S, Delarue M, André-Leroux G, Jarlier V, Aubry A, Mayer C. 2010. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 5:e12245. http://dx.doi.org/10.1371/journal.pone.0012245.
16. Li J, Gao X, Luo T, Wu J, Sun G, Liu Q, Jiang Y, Zhang Y, Mei J, Gao Q. 2014. Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerg Microbes Infect 3:e19. http://dx.doi.org/10.1038/emi.2014.21.
17. Willby M, Sikes RD, Malik S, Metchock B, Posey JE. 2015. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:5427-5434. http://dx.doi.org/10.1128/AAC.00662-15.
18. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR. 2012. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol 50:1390-1396. http://dx.doi.org/10.1128/JCM.05286-11.
19. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819-831. http://dx.doi.org/10.1093/jac/dkr566.
20. Pantel A, Petrella S, Matrat S, Brossier F, Bastian S, Reitter D, Jarlier V, Mayer C, Aubry A. 2011. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:4524-4529. http://dx.doi.org/10.1128/AAC.00707-11.
21. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. http://dx.doi.org/10.1371/journal.pone.0039754.
22. CLSI. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. CLSI document M24-A. Clinical and Laboratory Standards Institue, Wayne, PA.
23. WHO. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva, Switzerland.
24. WHO. 2012. Updated interim critical concentrations for first-line and second-line DST. http://www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table-1st%20and%202nd%20line%20drugs.pdf. Accessed 6 May 2016.
25. van Helden PD, Victor TC, Warren RM, van Helden EG. 2001. Isolation of DNA from Mycobactetirum tuberculosis. In Parish T, Stoker NG (ed), Mycobcateirum tuberculosis protocols. Humana Press, Totowa, NJ.
26. Hall TA. 1999. BioEdit: a user-friendly biological seqeunce alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser (Oxf) 41:95-98.
27. Disratthakit A, Meada S, Prammananan T, Thaipisuttikul I, Doi N, Chaiprasert A. 2015. Genotypic diversity of multidrug-, quinolone- and extensively drug-resistant Mycobacterium tuberculosis isolates in Thailand. Infect Genet Evol 32:432-439. http://dx.doi.org/10.1016/j.meegid.2015.03.038.
28. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907-914.
29. CLSI. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institue, Wayne, PA.
30. Onodera Y, Tanaka M, Sato K. 2001. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J Antimicrob Chemother 47:447-450. http://dx.doi.org/10.1093/jac/47.4.447.
31. Coll F, McNerney R, Guerra-Assuncao JA, Glynn JR, Perdigao J, Viveiros M, Portugal I, Pain A, Martin N, Clark TG. 2014. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun 5:4812. http://dx.doi.org/10.1038/ncomms5812.
32. Comas I, Homolka S, Niemann S, Gagneux S. 2009. Genotyping of genetically monomorphic bacteria: DNA sequencing in Mycobacterium tuberculosis highlights the limitations of current methodologies. PLoS One 4:e7815. http://dx.doi.org/10.1371/journal.pone.0007815.
33. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 51:6-14. http://dx.doi.org/10.1086/653115.
34. Jo KW, Lee SD, Kim WS, Kim DS, Shim TS. 2014. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 18:39-43. http://dx.doi.org/10.5588/ijtld.13.0307.
35. Seung KJ, Becerra MC, Atwood SS, Alcantara F, Bonilla CA, Mitnick CD. 2014. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect 20:441-446. http://dx.doi.org/10.1111/1469-0691.12335.
36. WHO. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
37. Mokrousov I, Otten T, Manicheva O, Potapova Y, Vishnevsky B, Narvskaya O, Rastogi N. 2008. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 52:2937-2939. http://dx.doi.org/10.1128/AAC.00036-08.
38. Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJ, Hossain MA, Fissette K, Rieder HL, Meehan CJ, de Jong BC, Van Deun A. 2016. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother 71:314-323. http://dx.doi.org/10.1093/jac/dkv360.
39. Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, Singh M. 2015. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. J Antibiot (Tokyo) 68:63-66. http://dx.doi.org/10.1038/ja.2014.95.
40. Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. 2014. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother 58:364-369. http://dx.doi.org/10.1128/AAC.01228-13.
41. Aldred KJ, Blower TR, Kerns RJ, Berger JM, Osheroff N. 2016. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci U S A http://dx.doi.org/10.1073/pnas.1525055113.
42. Blower TR, Williamson BH, Kerns RJ, Berger JM. 2016. Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A http://dx.doi.org/10.1073/pnas.1525047113.
43. Borrell S, Teo Y, Giardina F, Streicher EM, Klopper M, Feldmann J, Müller B, Victor TC, Gagneux S. 2013. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Public Health 2013:65-74. http://dx.doi.org/10.1093/emph/eot003.
44. Marcusson LL, Frimodt-Møller N, Hughes D. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5:e1000541. http://dx.doi.org/10.1371/journal.ppat.1000541.
45. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E. 2004. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 48:1281-1288. http://dx.doi.org/10.1128/AAC.48.4.1281-1288.2004.
46. Renau TE, Gage JW, Dever JA, Roland GE, Joannides ET, Shapiro MA, Sanchez JP, Gracheck SJ, Domagala JM, Jacobs MR, Reynolds RC. 1996. Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob Agents Chemother 40:2363-2368.
47. Renau TE, Sanchez JP, Gage JW, Dever JA, Shapiro MA, Gracheck SJ, Domagala JM. 1996. Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7. J Med Chem 39:729-735. http://dx.doi.org/10.1021/jm9507082.
48. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da Silva PA. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 53:4498-4500. http://dx.doi.org/10.1128/AAC.00287-09.
49. Regmi SM, Chaiprasert A, Coker OO, Disratthakit A, Prammananan T, Suriyaphol P, Yik-Ying T, Twee Hee O. 2015. Draft genome sequence of an extensively drug-resistant Mycobacterium tuberculosis Manu-Ancestor Spoligo-International Type 523 isolate from Thailand. Genome Announcements 3:e01589-14. http://dx.doi.org/10.1128/genomeA.01589-14.
50. Outhred AC, Jelfs P, Suliman B, Hill-Cawthorne GA, Crawford ABH, Marais BJ, Sintchenko V. 2015. Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother 70:1198-1202. http://dx.doi.org/10.1093/jac/dku508.
51. Witney AA, Gould KA, Arnold A, Coleman D, Delgado R, Dhillon J, Pond MJ, Pope CF, Planche TD, Stoker NG, Cosgrove CA, Butcher PD, Harrison TS, Hinds J. 2015. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol 53:1473-1483. http://dx.doi.org/10.1128/JCM.02993-14.